BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Blinatumomab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Blinatumomab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06387121-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06387121)
DESCRIPTION:Blinatumomab\, phase 2.\nStudy: Efficacy and Safety of Low-dose
  Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-AL
 L\nEstimated primary completion: 1 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06387121
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03114865-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT03114865)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL a
 s Post-allo-HSCT Remission Maintenance\nEstimated primary completion: 30 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatu
 momab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03114865
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06339775-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Blinatumomab: Phase 4 readout est. (NCT06339775)
DESCRIPTION:Blinatumomab\, phase 4.\nStudy: Blinatumomab for Relapsed Acute
  B Lymphoblastic Leukemia After Transplantation\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06339775
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06886074-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06886074)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL\nEstim
 ated primary completion: January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06886074
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519579-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT05519579)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blin
 atumomab Therapy for Acute Lymphoblastic Leukemia\nEstimated primary compl
 etion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05519579
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03739814-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT03739814)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treati
 ng Patients With Newly Diagnosed\, Recurrent\, or Refractory CD22-Positive
  B-Lineage Acute Lymphoblastic Leukemia\nEstimated primary completion: 1 F
 ebruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatu
 momab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03739814
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003737-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Blinatumomab: Phase na readout est. (NCT07003737)
DESCRIPTION:Blinatumomab\, phase na\, Acute Lymphoblastic Leukemia.\nStudy:
  Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic 
 Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation\nEstima
 ted primary completion: 5 February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07003737
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03147612-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT03147612)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Low-Intensity Chemotherapy\, Ponatinib and Blinatumomab in Treating Patien
 ts With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lym
 phoblastic Leukemia\nEstimated primary completion: 28 February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03147612
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04329325-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT04329325)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadel
 phia Chromosome-Positive Acute Lymphoblastic Leukemia\nEstimated primary c
 ompletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04329325
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06308588-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT06308588)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : Phase I/II Study of the Combination of Blinatumomab and Asciminib in Pat
 ients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia\n
 Estimated primary completion: 1 May 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06308588
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07921550-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Blinatumomab: Phase na readout est. (NCT07921550)
DESCRIPTION:Blinatumomab\, phase na.\nStudy: Venetoclax Plus Inotuzumab Red
 uced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL\nE
 stimated primary completion: 1 May 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07921550
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03595917-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT03595917)
DESCRIPTION:Blinatumomab\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: 
 ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML\nE
 stimated primary completion: 1 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03595917
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07199855-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07199855)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HS
 CT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia\nEstimated
  primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07199855
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722848-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT04722848)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and I
 matinib in Newly Diagnosed Adult Ph+ ALL\nEstimated primary completion: Se
 ptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatu
 momab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04722848
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05327894-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT05327894)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearra
 nged ALL or Mixed Phenotype Acute Leukemia\nEstimated primary completion: 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blina
 tumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05327894
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03914625-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT03914625)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study to Investigate Blinatumomab in Combination With Chemotherapy in Pa
 tients With Newly Diagnosed B-Lymphoblastic Leukemia\nEstimated primary co
 mpletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/blinatumomab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03914625
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07852234-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07852234)
DESCRIPTION:Blinatumomab\, phase 2.\nStudy: Exploratory Study on the Effica
 cy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Sev
 ere Primary Sjögren's Syndrome\nEstimated primary completion: 1 October 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0785223
 4
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07723911-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271010
DTEND;VALUE=DATE:20271011
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT07723911)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R
  CD19+ B-ALL\nEstimated primary completion: 10 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07723911
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930105-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06930105)
DESCRIPTION:Blinatumomab\, phase 2.\nStudy: Impact of Low-intensity Chemoth
 erapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With 
 Ph- B-ALL\nEstimated primary completion: 1 November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06930105
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04521231-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271124
DTEND;VALUE=DATE:20271125
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT04521231)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study of Subcutaneous Blinatumomab Administration in Participants With
  R/R and MRD+ B-ALL\nEstimated primary completion: 24 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04521231
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03263572-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT03263572)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab\, Methotrexate\, Cytarabine\, and Ponatinib in Treating Patie
 nts With Philadelphia Chromosome-Positive\, or BCR-ABL Positive\, or Relap
 sed/Refractory\, Acute Lymphoblastic Leukemia\nEstimated primary completio
 n: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03263572
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04872790-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT04872790)
DESCRIPTION:Blinatumomab\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: 
 Venetoclax\, Dasatinib\, Prednisone\, Rituximab and Blinatumomab for the T
 reatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive A
 cute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia\nEstimated p
 rimary completion: 2 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04872790
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789107-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271207
DTEND;VALUE=DATE:20271208
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT06789107)
DESCRIPTION:Blinatumomab\, phase 1\, Systemic Lupus Erythematosus.\nStudy: 
 Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus\n
 Estimated primary completion: 7 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06789107
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01371630-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271225
DTEND;VALUE=DATE:20271226
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT01371630)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients 
 With Acute Lymphoblastic Leukemia\nEstimated primary completion: 25 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT013
 71630
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706205-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT07706205)
DESCRIPTION:Blinatumomab\, phase 1.\nStudy: Safety and Efficacy of the Bisp
 ecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible 
 Living Donor Kidney Transplantation\nEstimated primary completion: 31 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumom
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7706205
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105579-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07105579)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in 
 Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantati
 on for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07105579
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06985485-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06985485)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline
  Chemotherapy\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06985485
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564453-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07564453)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-
 cell Acute Lymphoblastic Leukemia\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 64453
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573670-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07573670)
DESCRIPTION:Blinatumomab\, phase 2.\nStudy: A Phase 2 Study of Bcl-2 Inhibi
 tor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Le
 ukemia\nEstimated primary completion: 31 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07573670
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301424-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07301424)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07301424
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645718-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT05645718)
DESCRIPTION:Blinatumomab\, phase 2.\nStudy: Study of Pedi-cRIB: Mini-Hyper-
 CVD With Condensed Rituximab\, Inotuzumab Ozogamicin and Blinatumomab (cRI
 B) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocyti
 c Leukemia\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05645718
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06763302-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Blinatumomab: Phase na readout est. (NCT06763302)
DESCRIPTION:Blinatumomab\, phase na\, Acute Lymphoblastic Leukemia.\nStudy:
  NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL\nEstimated prim
 ary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06763302
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454226-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Blinatumomab: Phase na readout est. (NCT07454226)
DESCRIPTION:Blinatumomab\, phase na\, Acute Lymphoblastic Leukemia.\nStudy:
  ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL\nEsti
 mated primary completion: 1 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07454226
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07495631-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Blinatumomab: Phase na readout est. (NCT07495631)
DESCRIPTION:Blinatumomab\, phase na\, Acute Lymphoblastic Leukemia.\nStudy:
  Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for
  Adult Ph-Negative Acute Lymphoblastic Leukemia\nEstimated primary complet
 ion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bl
 inatumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07495631
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06836973-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Blinatumomab: Phase 2/3 readout est. (NCT06836973)
DESCRIPTION:Blinatumomab\, phase 2/3.\nStudy: Blinatumomab for Treatment of
  Refractory Myasthenia Gravis\nEstimated primary completion: 31 March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06836973
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493161-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Blinatumomab: Phase na readout est. (NCT07493161)
DESCRIPTION:Blinatumomab\, phase na.\nStudy: Chemotherapy With Targeted-Imm
 unotherapy for Newly Diagnosed Ph+ ALL\nEstimated primary completion: 31 M
 arch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumom
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7493161
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06507514-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT06507514)
DESCRIPTION:Blinatumomab\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for 
 B-ALL\nEstimated primary completion: 1 April 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06507514
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533748-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06533748)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphobla
 stic Leukemia and Lymphoma\nEstimated primary completion: May 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06533748
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643103-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07643103)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adu
 lt Ph-Negative B-ALL: A Prospective Umbrella Trial\nEstimated primary comp
 letion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07643103
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840976-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07840976)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult
  Ph+ B-ALL\nEstimated primary completion: 31 May 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07840976
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133997-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT07133997)
DESCRIPTION:Blinatumomab\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: 
 Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinat
 umomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Ac
 ute Lymphoblastic Leukemia\nEstimated primary completion: 1 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07133997
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04546399-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT04546399)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Pa
 tients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B
 -ALL)\nEstimated primary completion: 30 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04546399
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04530565-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT04530565)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumom
 ab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblasti
 c Leukemia in Adults\nEstimated primary completion: 1 July 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04530565
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03643276-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT03643276)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Treatment Protocol for Children and Adolescents With Acute Lymphoblastic L
 eukemia - AIEOP-BFM ALL 2017\nEstimated primary completion: 14 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03643276
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570798-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280806
DTEND;VALUE=DATE:20280807
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06570798)
DESCRIPTION:Blinatumomab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: 
 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoi
 mmune Diseases\nEstimated primary completion: 6 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06570798
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07914166-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT07914166)
DESCRIPTION:Blinatumomab\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: 
 Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Phi
 ladelphia Chromosome-Positive Acute Lymphoblastic Leukemia\nEstimated prim
 ary completion: 13 October 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07914166
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02877303-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT02877303)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Blinatumomab\, Inotuzumab Ozogamicin\, and Combination Chemotherapy as Fro
 ntline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia\nE
 stimated primary completion: 1 November 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02877303
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677878-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT07677878)
DESCRIPTION:Blinatumomab\, phase 1.\nStudy: Blinatumomab Combined With Low-
 dose DLI as Maintenance Therapy After Transplantation for B-ALL\nEstimated
  primary completion: 30 November 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07677878
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052370-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT07052370)
DESCRIPTION:Blinatumomab\, phase 1.\nStudy: TCRαβ-depleted Progenitor Cel
 l Graft With Early Memory T-cell DLI\, Plus Selected Use of Blinatumomab\,
  in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transpl
 antation for Hematologic Malignancies\nEstimated primary completion: Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumoma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 052370
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848687-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT05848687)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II\n
 Estimated primary completion: December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05848687
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06287229-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT06287229)
DESCRIPTION:Blinatumomab\, phase 1/2.\nStudy: Phase Ib/II Study Assessing t
 he Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolid
 ation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cel
 l Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotu
 zumab-blinatumomab/HCVAD-inotuzumab-blinatumomab\nEstimated primary comple
 tion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06287229
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317662-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06317662)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-ca
 ncer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for In
 fants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukem
 ia\nEstimated primary completion: 31 December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06317662
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686042-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Blinatumomab: Phase 4 readout est. (NCT07686042)
DESCRIPTION:Blinatumomab\, phase 4.\nStudy: Efficacy and Safety of Low-Dose
  Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and A
 utoimmune Cerebellitis\nEstimated primary completion: 31 December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07686042
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07313852-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT07313852)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymph
 oblastic Leukemia\nEstimated primary completion: January 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07313852
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07869368-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT07869368)
DESCRIPTION:Blinatumomab\, phase 1.\nStudy: BLinatumomab and iNKT in Relaps
 ed B-Cell ALL\nEstimated primary completion: February 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07869368
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06061094-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06061094)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy\, Imat
 inib or Ponatinib\, Blinatumomab and SCT\nEstimated primary completion: 1 
 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumom
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6061094
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222579-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07222579)
DESCRIPTION:Blinatumomab\, phase 2.\nStudy: Subcutaneous Blinatumomab for T
 reatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukem
 ia (MPAL)\nEstimated primary completion: August 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07222579
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283640-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT07283640)
DESCRIPTION:Blinatumomab\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumeni
 b for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia\nEstimat
 ed primary completion: 31 August 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07283640
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04994717-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT04994717)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy V
 ersus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed 
 Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia\nEstim
 ated primary completion: 7 September 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04994717
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04260022-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20291227
DTEND;VALUE=DATE:20291228
SUMMARY:Blinatumomab: Phase 1 readout est. (NCT04260022)
DESCRIPTION:Blinatumomab\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: 
 Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL\nEstimated pr
 imary completion: 27 December 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04260022
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06882057-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Blinatumomab: Phase 2/3 readout est. (NCT06882057)
DESCRIPTION:Blinatumomab\, phase 2/3\, Acute Lymphoblastic Leukemia.\nStudy
 : Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol\nEstimated primar
 y completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06882057
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764238-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Blinatumomab: Phase 2/3 readout est. (NCT06764238)
DESCRIPTION:Blinatumomab\, phase 2/3\, Acute Lymphoblastic Leukemia.\nStudy
 : Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol\nEs
 timated primary completion: 31 December 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06764238
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06991920-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Blinatumomab: Phase na readout est. (NCT06991920)
DESCRIPTION:Blinatumomab\, phase na.\nStudy: Immune-targeted Combination Wi
 th Chemotherapy for Acute Leukemia of Ambiguous Lineage\nEstimated primary
  completion: 1 April 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/blinatumomab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06991920
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227584-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07227584)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 ALL Backbone in AYAs\nEstimated primary completion: 31 July 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07227584
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192237-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20301012
DTEND;VALUE=DATE:20301013
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07192237)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumom
 ab in Patients With Measurable Residual Disease Positive B-cell Acute Lymp
 hoblastic Leukemia\nEstimated primary completion: 12 October 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07192237
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06124157-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT06124157)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy T
 reatment With Blinatumomab for Children\, Adolescents\, and Young Adults W
 ith Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chrom
 osome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)\nEstimate
 d primary completion: 1 December 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06124157
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134088-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20310306
DTEND;VALUE=DATE:20310307
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT07134088)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B
 -Cell Precursor Acute Lymphoblastic Leukemia\nEstimated primary completion
 : 6 March 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/blina
 tumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07134088
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07443592-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20310306
DTEND;VALUE=DATE:20310307
SUMMARY:Blinatumomab: Phase na readout est. (NCT07443592)
DESCRIPTION:Blinatumomab\, phase na\, Acute Lymphoblastic Leukemia.\nStudy:
  Treatment for Ph-negative ALL for Adults up to 65 Years\nEstimated primar
 y completion: 6 March 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/blinatumomab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07443592
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636564-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20310416
DTEND;VALUE=DATE:20310417
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07636564)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acu
 te Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment\n
 Estimated primary completion: 16 April 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07636564
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604233-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20310603
DTEND;VALUE=DATE:20310604
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT07604233)
DESCRIPTION:Blinatumomab\, phase 1/2.\nStudy: Phase 1/2 FLAG-IDA\, VEN and 
 Asciminib in CML and Ph+ AML\nEstimated primary completion: 3 June 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07604233
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153796-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT07153796)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Bli
 natumomab in Combination With Low Intensity Chemotherapy in Older Patients
  With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia\nEstimated prima
 ry completion: 30 September 2031. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07153796
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178912-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT07178912)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverem
 batinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR:
 :ABL1 Positive Acute Lymphoblastic Leukemia (ALL)\nEstimated primary compl
 etion: 30 September 2031. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07178912
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223190-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT07223190)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly D
 iagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia\nEstim
 ated primary completion: 30 December 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07223190
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294677-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT07294677)
DESCRIPTION:Blinatumomab\, phase 1/2.\nStudy: CApivasertib\, Venetoclax And
  Low-intensity chemotheRapY for Adults With ALL/LBL\nEstimated primary com
 pletion: March 2032. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 blinatumomab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07294677
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03959085-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT03959085)
DESCRIPTION:Blinatumomab\, phase 3\, Acute Lymphoblastic Leukemia.\nStudy: 
 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients
  With High-Risk B-ALL\, Mixed Phenotype Acute Leukemia\, and B-LLy\nEstima
 ted primary completion: 31 March 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03959085
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827549-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Blinatumomab: Phase 2 readout est. (NCT05827549)
DESCRIPTION:Blinatumomab\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: 
 Evaluation of Treatment Efficacy According to Risk Group in Relapsed Child
 hood Acute Lymphoblastic Leukemia\nEstimated primary completion: 31 Decemb
 er 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 27549
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07476729-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT07476729)
DESCRIPTION:Blinatumomab\, phase 3.\nStudy: International Study for Treatme
 nt of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)\nEs
 timated primary completion: 31 March 2033. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07476729
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04307576-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Blinatumomab: Phase 3 readout est. (NCT04307576)
DESCRIPTION:Blinatumomab\, phase 3.\nStudy: A Treatment Study Protocol for 
 Participants 0-45 Years With Acute Lymphoblastic Leukaemia\nEstimated prim
 ary completion: June 2033. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/blinatumomab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04307576
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387926-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20330919
DTEND;VALUE=DATE:20330920
SUMMARY:Blinatumomab: Phase 1/2 readout est. (NCT07387926)
DESCRIPTION:Blinatumomab\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy
 : Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Rel
 apse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acu
 te Lymphoblastic Leukemia (ALL)\nEstimated primary completion: 19 Septembe
 r 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/blinatumomab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0738
 7926
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860269-5633@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20350315
DTEND;VALUE=DATE:20350316
SUMMARY:Blinatumomab: Phase 2/3 readout est. (NCT06860269)
DESCRIPTION:Blinatumomab\, phase 2/3\, Acute Lymphoblastic Leukemia.\nStudy
 : A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic
  Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) i
 n Frontline Therapy of Adults With Acute Lymphoblastic Leukemia\nEstimated
  primary completion: 15 March 2035. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/blinatumomab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06860269
URL:https://assetmemo.bio/drug/blinatumomab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
